Previous 10 | Next 10 |
MIAMI, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today a...
MIAMI, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today a...
Avenue Therapeutics press release ( NASDAQ: ATXI ): Q3 GAAP EPS of -$0.45. As of September 30, 2022, Avenue’s cash and cash equivalents totaled $0.2M, compared to $3.8M at December 31, 2021. For further details see: Avenue Therapeutics GAAP EPS of -$0.45 ...
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases...
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system (“...
Penny Stocks Trading Must Knows Right Now Penny stocks can be a great way to get started trading, especially if you’re new to investing and don’t have a lot of money to invest. These low-priced stocks are often overlooked by investors focused on more high-profile investmen...
NEW YORK, NY / ACCESSWIRE / October 12, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI). About Avenue Therapeutics, Inc. Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops a...
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases...
Avenue Therapeutics ( NASDAQ: ATXI ) is down 10.8% after-hours after the firm has priced its underwritten public offering of 3,636,365 common and pre-funded units. Each common unit consists of one share of common stock and one warrant to purchase one share of common st...
NEW YORK, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases...
News, Short Squeeze, Breakout and More Instantly...
Avenue Therapeutics Inc. Company Name:
ATXI Stock Symbol:
NASDAQ Market:
Avenue Therapeutics Inc. Website:
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the ...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutica...